TB006

Phase 2Small molecule

TTrueBinding, Inc.

TB006 is one of 84 small molecule programs targeting Autism Spectrum Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autism Spectrum DisorderActive, not recruiting

COVID-19Active, not recruiting

Ischemic StrokeActive, not recruiting

Autism Spectrum DisorderPhase 2

Active, not recruiting

COVID-19Phase 1

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Stivarga

Bayer

Preclinical

1 3

Aimovig

Amgen

Preclinical

1 4

Aldactone

Pfizer

Preclinical

1 5

Nexavar

Bayer

Preclinical

1 6

TB006

TTrueBinding, Inc.

Phase 2

1 7

Activella

Benadryl

1 9

Rayaldee

OOrganon and Co

Preclinical

1 10

Statins

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Autism Spectrum Disorder

NCT06500637

Phase 2Recruiting

Parkinson's Disease

NCT06773962

Clinical

Trials by Indication[1]

Alzheimer's Disease2 trials

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

Terminated·TTrueBinding, Inc.·Phase 2·NCT05476783·180 enrolled

Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease

Completed·TTrueBinding, Inc.·Phase 1/2·NCT05074498·154 enrolled

Autism Spectrum Disorder1 trial

TB006 for Autism Spectrum Disorder

Recruiting·RRossignol Medical Center·Phase 2·NCT06500637·45 enrolled

ESS1 trial

TB006 Expanded Access (EA) Compassionate Use

Available·TTrueBinding, Inc.··NCT05959239

Tics1 trial

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

Completed·TTrueBinding, Inc.·Phase 1·NCT04920786·48 enrolled

Ischemic stroke1 trial

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke

Withdrawn·TTrueBinding, Inc.·Phase 2·NCT05156827

2 more indications

Parkinson's Disease1 trial

A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease

Recruiting·TTrueBinding, Inc.·Phase 2·NCT06773962·62 enrolled

COVID-191 trial

Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19

Withdrawn·TTrueBinding, Inc.·Phase 1·NCT04801056

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for TB006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TB006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TB006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — TrueBinding, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTrueBinding, Inc.

TB006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Alzheimer's Disease2 trials

Autism Spectrum Disorder1 trial

ESS1 trial

Tics1 trial

Ischemic stroke1 trial

Parkinson's Disease1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News